Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Groenhuysen Wilhelmus CmOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,217Price:$16.01
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-840Price:$16.01
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Groenhuysen Wilhelmus CmOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,107Price:$16.03
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,679Price:$16.03
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,078Price:$16.14
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Groenhuysen Wilhelmus CmOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,303Price:$16.14
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Cordova AshleyOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:156,348Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Cordova AshleyOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:102,249Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:156,348Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:102,249Price:$16.30
Filings by filing date
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Groenhuysen Wilhelmus CmOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,217Price:$16.01
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Groenhuysen Wilhelmus CmOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,107Price:$16.03
-
Mar 04, 2024 (filed on Mar 05, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-840Price:$16.01
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,679Price:$16.03
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Cordova AshleyOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:156,348Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Cordova AshleyOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:102,249Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:156,348Price:$16.30
-
Feb 28, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,078Price:$16.14
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Leonard Frank XOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:102,249Price:$16.30
-
Feb 27, 2024 (filed on Feb 29, 2024)Insider Name:Puri Michal NathOwnership Type:Direct OwnershipSecurities:Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:109,443Price:$16.30
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | No. 4 The Forum, Grenville Street SAINT HELIER JE2 4UF |
Tel: | N/A |
Website: | https://www.novocure.com |
IR: | See website |
Key People | ||
William F. Doyle Executive Chairman of the Board | Asaf Danziger President, Chief Executive Officer, Director | Ashley Cordova Chief Financial Officer |
Wilhelmus C. M. Groenhuysen Chief Operating Officer | William Burke Chief Human Resource Officer | Frank X. Leonard Executive Vice President and President - Novocure Oncology |
Barak Ben-Arye General Counsel | Nicholas Leupin Chief Medical Officer | Uri Weinberg Chief Innovation Officer |
Business Overview |
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. |
Financial Overview |
For the three months ended 31 March 2024, Novocure Ltd revenues increased 13% to $138.5M. Net loss decreased 27% to $38.8M. Revenues reflect Other EMEA countries segment increase from $7.9M to $19.5M, United States segment increase of 6% to $90.5M. Lower net loss reflects Research, development and clinical decrease of 10% to $43M (expense), Stock-based Compensation in R&D decrease of 27% to $8.6M (expense). |
Employees: | 1,453 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,290M as of Mar 31, 2024 |
Annual revenue (TTM): | $525.66M as of Mar 31, 2024 |
EBITDA (TTM): | -$203.07M as of Mar 31, 2024 |
Net annual income (TTM): | -$192.74M as of Mar 31, 2024 |
Free cash flow (TTM): | -$120.97M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 107,611,077 as of Apr 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |